The Potential Nexus between Helminths and SARS-CoV-2 Infection: A Literature Review

Chronic helminth infections (CHIs) can induce immunological tolerance through the upregulation of regulatory T cells. In coronavirus disease 2019 (COVID-19), abnormal adaptive immune response and exaggerated immune response may cause immune-mediated tissue damage. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and CHIs establish complicated immune interactions due to SARS-CoV-2-induced immunological stimulation and CHIs-induced immunological tolerance. However, COVID-19 severity in patients with CHIs is mild, as immune-suppressive anti-inflammatory cytokines counterbalance the risk of cytokine storm. Since CHIs have immunomodulatory effects, therefore, this narrative review aimed to clarify how CHIs modulate the immunoinflammatory response in SARS-CoV-2 infection. CHIs, through helminth-derived molecules, may suppress SARS-CoV-2 entry and associated hyperinflammation through attenuation of the inflammatory signaling pathway. In addition, CHIs may reduce the COVID-19 severity by reducing the SARS-CoV-2 entry points in the initial phase and immunomodulation in the late phase of the disease by suppressing the release of pro-inflammatory cytokines. In conclusion, CHIs may reduce the severity of SARS-CoV-2 infection by reducing hyperinflammation and exaggerated immune response. Thus, retrospective and prospective studies are recommended in this regard.

[1]  O. Turriziani,et al.  Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection , 2023, Circulation research.

[2]  Ali I. Al-Gareeb,et al.  Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal , 2022, Inflammopharmacology.

[3]  Ali I. Al-Gareeb,et al.  Common NLRP3 inflammasome inhibitors and Covid-19: Divide and conquer , 2022, Scientific African.

[4]  Ali I. Al-Gareeb,et al.  Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy? , 2022, Inflammopharmacology.

[5]  Ali I. Al-Gareeb,et al.  Potential role of lipoxin in the management of COVID-19: a narrative review , 2022, Inflammopharmacology.

[6]  Ali I. Al-Gareeb,et al.  Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals , 2022, Inflammopharmacology.

[7]  A. Alexiou,et al.  Cannabinoids receptors in Covid-19: Perpetrators and victims. , 2022, Current Medicinal Chemistry.

[8]  E. Calderón,et al.  Overlapping of Pulmonary Fibrosis of Postacute COVID-19 Syndrome and Tuberculosis in the Helminth Coinfection Setting in Sub-Saharan Africa , 2022, Tropical medicine and infectious disease.

[9]  Ali I. Al-Gareeb,et al.  Hemolytic anemia in COVID-19 , 2022, Annals of Hematology.

[10]  G. Sivasubramanian,et al.  Strongyloides Hyperinfection Syndrome among COVID-19 Patients Treated with Corticosteroids , 2022, Emerging infectious diseases.

[11]  A. Hoerauf,et al.  Helminth antigens differentially modulate the activation of CD4+ and CD8+ T lymphocytes of convalescent COVID-19 patients in vitro , 2022, BMC Medicine.

[12]  Ali I. Al-Gareeb,et al.  High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons , 2022, Inflammopharmacology.

[13]  Ali I. Al-Gareeb,et al.  Selinexor and COVID-19: The Neglected Warden , 2022, Frontiers in Pharmacology.

[14]  Ali I. Al-Gareeb,et al.  Trimetazidine and COVID-19-induced acute cardiac injury: a missed key , 2022, International Journal of Clinical Pharmacy.

[15]  H. Bastiaens,et al.  Prevalence, intensity and endemicity of intestinal schistosomiasis and soil-transmitted helminthiasis and its associated factors among school-aged children in Southern Ethiopia , 2022, Scientific Reports.

[16]  G. Batiha,et al.  Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19 , 2022, Future science OA.

[17]  P. Bąska,et al.  The Role of Nuclear Factor Kappa B (NF-κB) in the Immune Response against Parasites , 2022, Pathogens.

[18]  Ali I. Al-Gareeb,et al.  Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality , 2022, International Immunopharmacology.

[19]  Ali I. Al-Gareeb,et al.  COVID-19 and erythrocrine function: The roller coaster and danger , 2022, International journal of immunopathology and pharmacology.

[20]  E. Calderón,et al.  Prevalence of Pneumocystosis in Sub-Saharan Africa and Helminth Immune Modulation , 2021, Journal of fungi.

[21]  Wasihun Hailemichael,et al.  Immunomodulation of COVID‐19 severity by helminth co‐infection: Implications for COVID‐19 vaccine efficacy , 2021, Immunity, inflammation and disease.

[22]  Ali I. Al-Gareeb,et al.  Niclosamide for Covid-19: bridging the gap , 2021, Molecular Biology Reports.

[23]  M. Ademe,et al.  The Influence of Helminth Immune Regulation on COVID-19 Clinical Outcomes: Is it Beneficial or Detrimental? , 2021, Infection and drug resistance.

[24]  Ali I. Al-Gareeb,et al.  Covid-19 and development of heart failure: mystery and truth , 2021, Naunyn-Schmiedeberg's Archives of Pharmacology.

[25]  Mehran Ghasemzadeh,et al.  Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice , 2021, Human Immunology.

[26]  Ali I. Al-Gareeb,et al.  Impact of Sitagliptin in Non-Diabetic Covid-19 Patients. , 2021, Current molecular pharmacology.

[27]  Ali I. Al-Gareeb,et al.  The potential role of neopterin in Covid-19: a new perspective , 2021, Molecular and Cellular Biochemistry.

[28]  Ali I. Al-Gareeb,et al.  The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections , 2021, Life.

[29]  K. Alene,et al.  The prevalence of tuberculosis, malaria and soil-transmitted helminth infection in minority indigenous people of Southeast Asia and the Western Pacific: protocol for a systematic review and meta-analysis , 2021, Systematic Reviews.

[30]  R. Maizels,et al.  Helminth extracellular vesicles: Interactions with the host immune system , 2021, Molecular immunology.

[31]  Pei-Hsuan Chen,et al.  Inhibiting adipose tissue M1 cytokine expression decreases DPP4 activity and insulin resistance in a type 2 diabetes mellitus mouse model , 2021, PloS one.

[32]  A. Rodríguez-Morales,et al.  Emerging issues in COVID-19 vaccination in tropical areas: Impact of the immune response against helminths in endemic areas , 2021, Travel Medicine and Infectious Disease.

[33]  Ali I. Al-Gareeb,et al.  COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus , 2021, Frontiers in Cardiovascular Medicine.

[34]  A. Rodríguez-Morales,et al.  COVID-19 and helminth infection: Beyond the Th1/Th2 paradigm , 2021, PLoS neglected tropical diseases.

[35]  Ali I. Al-Gareeb,et al.  Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives , 2021, Frontiers in Pharmacology.

[36]  T. R. D. de Wit,et al.  Effect of co-infection with intestinal parasites on COVID-19 severity: A prospective observational cohort study , 2021, EClinicalMedicine.

[37]  T. F. Rinke de Wit,et al.  Interrogating the Impact of Intestinal Parasite-Microbiome on Pathogenesis of COVID-19 in Sub-Saharan Africa , 2021, Frontiers in Microbiology.

[38]  S. Madhi,et al.  Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.

[39]  Ali I. Al-Gareeb,et al.  Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects , 2021, Pulmonary Pharmacology & Therapeutics.

[40]  M. Pistis,et al.  Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology , 2021, Frontiers in Pharmacology.

[41]  T. Pennington.  Herd immunity: could it bring the COVID-19 pandemic to an end? , 2021, Future microbiology.

[42]  Khalid J. Alzahrani,et al.  A Descriptive-Multivariate Analysis of Community Knowledge, Confidence, and Trust in COVID-19 Clinical Trials among Healthcare Workers in Uganda , 2021, Vaccines.

[43]  S. Gennai,et al.  Do Blood Eosinophils Predict in-Hospital Mortality or Severity of Disease in SARS-CoV-2 Infection? A Retrospective Multicenter Study , 2021, Microorganisms.

[44]  P. Chiodini,et al.  Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19 , 2021, Travel Medicine and Infectious Disease.

[45]  N. Rezaei,et al.  Role of Toll‐like receptors in the pathogenesis of COVID‐19 , 2021, Journal of medical virology.

[46]  P. Gueudet,et al.  Eosinopenia <100/μL as a marker of active COVID-19: An observational prospective study , 2021, Journal of Microbiology, Immunology and Infection.

[47]  J. Laman,et al.  Between a hygiene rock and a hygienic hard place , 2021, Evolution, medicine, and public health.

[48]  M. Soni.  Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID‐19 infection , 2020, International journal of laboratory hematology.

[49]  G. W. Wong,et al.  Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19 , 2020, Biochemical and Biophysical Research Communications.

[50]  C. Neumann,et al.  The Many Functions of Foxp3+ Regulatory T Cells in the Intestine , 2020, Frontiers in Immunology.

[51]  Theresa E. Gildner,et al.  Old friends meet a new foe , 2020, Evolution, medicine, and public health.

[52]  R. Sanjuán,et al.  Potential Influence of Helminth Molecules on COVID-19 Pathology , 2020, Trends in Parasitology.

[53]  G. W. Wong,et al.  Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19 , 2020, bioRxiv.

[54]  G. García,et al.  COVID-19 Lethality in Sub-Saharan Africa and Helminth Immune Modulation , 2020, Frontiers in Immunology.

[55]  V. V. Lima,et al.  Angiotensin (1-7)-attenuated vasoconstriction is associated with the Interleukin-10 signaling pathway. , 2020, Life sciences.

[56]  Sunita Chhapola Shukla.  ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19 , 2020, European Archives of Oto-Rhino-Laryngology.

[57]  Ali I. Al-Gareeb,et al.  COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors , 2020, Journal of microscopy and ultrastructure.

[58]  A. Abdoli,et al.  Helminths and COVID-19 Co-Infections: A Neglected Critical Challenge. , 2020, ACS pharmacology & translational science.

[59]  A. Kerckhoffs,et al.  Immunosuppressive Drugs and COVID-19: A Review , 2020, Frontiers in Pharmacology.

[60]  Michael R Hamblin,et al.  Cytokines and COVID-19: friends or foes? , 2020, Human vaccines & immunotherapeutics.

[61]  P. Jorth,et al.  The Unrecognized Threat of Secondary Bacterial Infections with COVID-19 , 2020, mBio.

[62]  J. Eckel,et al.  DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? , 2020, Frontiers in Pharmacology.

[63]  A. Loukas,et al.  Helminth coinfection and COVID-19: An alternate hypothesis , 2020, PLoS neglected tropical diseases.

[64]  Hayder M Al-Kuraishy,et al.  Is ivermectin–Azithromycin combination the next step for COVID-19? , 2020 .

[65]  Li Yang,et al.  COVID-19: immunopathogenesis and Immunotherapeutics , 2020, Signal Transduction and Targeted Therapy.

[66]  B. Firestein,et al.  Colchicine in COVID-19: an Old Drug, New Use , 2020, Current Pharmacology Reports.

[67]  Chengliang Zhu,et al.  Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19 , 2020, Frontiers in Molecular Biosciences.

[68]  Hayder M Al-Kuraishy,et al.  Macrolides and COVID-19: An optimum premise , 2020 .

[69]  T. Swartz,et al.  Targeting the NLRP3 Inflammasome in Severe COVID-19 , 2020, Frontiers in Immunology.

[70]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[71]  D. Ragab,et al.  The COVID-19 Cytokine Storm; What We Know So Far , 2020, Frontiers in Immunology.

[72]  B. Gunn,et al.  Why is There Low Morbidity and Mortality of COVID-19 in Africa? , 2020, The American journal of tropical medicine and hygiene.

[73]  I. Amit,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[74]  S. Mukherjee,et al.  In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs , 2020, Journal of medical virology.

[75]  Z. Wang,et al.  Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study , 2020, EClinicalMedicine.

[76]  Hayder M Al-Kuraishy,et al.  COVID-19 pneumonia in an Iraqi pregnant woman with preterm delivery , 2020 .

[77]  A. Greenhill,et al.  Will helminth co-infection modulate COVID-19 severity in endemic regions? , 2020, Nature Reviews Immunology.

[78]  K. Ndashe,et al.  Immunity, parasites, genetics and sex hormones: contributors to mild inflammatory responses in COVID-19? , 2020, The Pan African medical journal.

[79]  P. Gergen,et al.  Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2 , 2020, Journal of Allergy and Clinical Immunology.

[80]  W. Miesbach.  Pathological Role of Angiotensin II in Severe COVID-19 , 2020, TH Open.

[81]  T. Nutman,et al.  Helminth infection modulates systemic pro-inflammatory cytokines and chemokines implicated in type 2 diabetes mellitus pathogenesis , 2020, PLoS neglected tropical diseases.

[82]  R. Maizels.  Regulation of immunity and allergy by helminth parasites , 2020, Allergy.

[83]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[84]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  R. Zhou,et al.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases , 2019, Nature Reviews Immunology.

[86]  A. Abdoli,et al.  Helminth infections and immunosenescence: The friend of my enemy , 2020, Experimental Gerontology.

[87]  R. Liu,et al.  Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.

[88]  A. Ivens,et al.  Helminth-induced Th2 cell dysfunction is distinct from exhaustion and is maintained in the absence of antigen , 2019, PLoS neglected tropical diseases.

[89]  Luis E. Arias-Romero,et al.  Helminth‐derived molecules inhibit colitis‐associated colon cancer development through NF‐κB and STAT3 regulation , 2019, International journal of cancer.

[90]  Judith N. Mandl,et al.  NK cell recruitment limits tissue damage during an enteric helminth infection , 2019, Mucosal Immunology.

[91]  G. Gabriel,et al.  Helminth Infections Suppress the Efficacy of Vaccination against Seasonal Influenza. , 2019, Cell reports.

[92]  S. Babayan,et al.  Variation in Local and Systemic Pro-Inflammatory Immune Markers of Wild Wood Mice after Anthelmintic Treatment , 2019, Integrative and comparative biology.

[93]  S. Babu,et al.  Helminth mediated modulation of the systemic and mycobacterial antigen – stimulated cytokine profiles in extra-pulmonary tuberculosis , 2019, PLoS neglected tropical diseases.

[94]  L. Mendez,et al.  Fasciola hepatica GST downregulates NF-κB pathway effectors and inflammatory cytokines while promoting survival in a mouse septic shock model , 2019, Scientific Reports.

[95]  A. Afolayan,et al.  Helminthiases; prevalence, transmission, host-parasite interactions, resistance to common synthetic drugs and treatment , 2019, Heliyon.

[96]  N. Mabbott.  The Influence of Parasite Infections on Host Immunity to Co-infection With Other Pathogens , 2018, Front. Immunol..

[97]  R. Maizels,et al.  Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules , 2018, Immunity.

[98]  P. Nejsum,et al.  Immunomodulation by Helminths: Intracellular Pathways and Extracellular Vesicles , 2018, Front. Immunol..

[99]  N. DiPatrizio,et al.  Host- and Helminth-Derived Endocannabinoids That Have Effects on Host Immunity Are Generated during Infection , 2018, Infection and Immunity.

[100]  P. Fallon,et al.  Helminth Modulation of Lung Inflammation. , 2018, Trends in parasitology.

[101]  K. Nakanishi.  Unique Action of Interleukin-18 on T Cells and Other Immune Cells , 2018, Front. Immunol..

[102]  M. Theumer,et al.  Helminth Infections: Recognition and Modulation of the Immune Response by Innate Immune Cells , 2018, Front. Immunol..

[103]  O. Haçarız,et al.  Genererating a core cluster of Fasciola hepatica virulence and immunomodulation-related genes using a comparative in silico approach. , 2018, Research in veterinary science.

[104]  B. Naziruddin,et al.  Ex-vivo generation of drug-eluting islets improves transplant outcomes by inhibiting TLR4-Mediated NFkB upregulation. , 2018, Biomaterials.

[105]  P. Gao,et al.  Deficiency of Complement C3a and C5a Receptors Prevents Angiotensin II–Induced Hypertension via Regulatory T Cells , 2018, Circulation research.

[106]  A. Canaris,et al.  Metazoan Parasites of the American Coot, Fulica americana, from the Rio Grande Valley in Colorado and Southwest, Texas, U.S.A., with a Checklist of Parasites for North America and West Indies , 2017, Comparative Parasitology.

[107]  M. Theisen,et al.  THE EFFECT OF HELMINTH CO-INFECTION ON MALARIA-SPECIFIC IMMUNOGLOBULIN G RESPONSES , 2017, BMJ Global Health.

[108]  M. Horton,et al.  mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis , 2017, Nature Communications.

[109]  J. Dalton,et al.  The immune modulatory peptide FhHDM‐1 secreted by the helminth Fasciola hepatica prevents NLRP3 inflammasome activation by inhibiting endolysosomal acidification in macrophages , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[110]  R. Maizels,et al.  Regulation of the host immune system by helminth parasites , 2016, The Journal of allergy and clinical immunology.

[111]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[112]  A. Buret,et al.  Gastrointestinal Parasites and the Neural Control of Gut Functions , 2015, Front. Cell. Neurosci..

[113]  R. Maizels,et al.  How helminths go viral , 2014, Science.

[114]  F. Bushman,et al.  Virus-helminth coinfection reveals a microbiota-independent mechanism of immunomodulation , 2014, Science.

[115]  J. McCullers,et al.  Secondary Bacterial Infections in Influenza Virus Infection Pathogenesis , 2014, Current topics in microbiology and immunology.

[116]  R. Maizels,et al.  Helminths and Immunological Tolerance , 2014, Transplantation.

[117]  J. Dalton,et al.  Helminth defence molecules—immunomodulators designed by parasites! , 2013, Front. Microbiol..

[118]  A. Hoerauf,et al.  Helminths and their implication in sepsis – a new branch of their immunomodulatory behaviour? , 2013, Pathogens and disease.

[119]  M. Zaiss,et al.  IL-1β Suppresses Innate IL-25 and IL-33 Production and Maintains Helminth Chronicity , 2013, PLoS pathogens.

[120]  Y. Djuardi,et al.  Helminth infection in populations undergoing epidemiological transition: a friend or foe? , 2012, Seminars in Immunopathology.

[121]  R. Xavier,et al.  Helminth Infection Impairs Autophagy-Mediated Killing of Bacterial Enteropathogens by Macrophages , 2012, The Journal of Immunology.

[122]  M. Torrero,et al.  Chronic Helminth Infection Reduces Basophil Responsiveness in an IL-10–Dependent Manner , 2012, The Journal of Immunology.

[123]  C. Rozo,et al.  An essential role for the Th2-type response in limiting tissue damage during helminth infection , 2011, Nature Medicine.

[124]  R. Maizels,et al.  Diversity and dialogue in immunity to helminths , 2011, Nature Reviews Immunology.

[125]  J. Tschopp,et al.  Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses , 2010, Proceedings of the National Academy of Sciences.

[126]  B. Everts,et al.  Helminths and dendritic cells: Sensing and regulating via pattern recognition receptors, Th2 and Treg responses , 2010, European journal of immunology.

[127]  B. Everts,et al.  Chronic Helminth Infections Protect Against Allergic Diseases by Active Regulatory Processes , 2010, Current allergy and asthma reports.

[128]  H. Sabzevari,et al.  Inhibition of TLR3 and TLR4 function and expression in human dendritic cells by helminth parasites. , 2008, Blood.

[129]  T. Löscher,et al.  Eosinophilia during intestinal infection. , 2008, Best practice & research. Clinical gastroenterology.

[130]  P. Kaleebu,et al.  Helminths and HIV infection: epidemiological observations on immunological hypotheses , 2006, Parasite immunology.

[131]  S. Kamal,et al.  Immune modulation by helminthic infections: worms and viral infections , 2006, Parasite immunology.

[132]  Z. Bentwich,et al.  Chronic Immune Activation Associated with Chronic Helminthic and Human Immunodeficiency Virus Infections: Role of Hyporesponsiveness and Anergy , 2004, Clinical Microbiology Reviews.

[133]  Ethan M. Shevach,et al.  Suppressor Effector Function of CD4+CD25+ Immunoregulatory T Cells Is Antigen Nonspecific , 2000, The Journal of Immunology.

[134]  S. Qusti,et al.  Cyclosporine Attenuates Covid-19: Ensnare or Victory , 2021 .

[135]  Daishi Tian,et al.  Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China , 2020 .

[136]  By,et al.  TAENIA SAGINATA IN MAN AND CYSTICERCOSIS IN CATTLE AND BUFFALOES IN ASWAN GOVERNORATE, EGYPT , 2017 .

[137]  R. Fujiwara,et al.  Concomitant helminth infection downmodulates the Vaccinia virus-specific immune response and potentiates virus-associated pathology. , 2017, International journal for parasitology.